RecruitingPhase 1Phase 2NCT05636618

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors

Sponsor

Perspective Therapeutics

Enrollment

300 participants

Start Date

Sep 27, 2023

Study Type

INTERVENTIONAL

Conditions

Paraganglioma Pheochromocytoma Meningioma Neuroendocrine Tumors Unresectable Neuroendocrine Tumor Metastatic Gastroenteropancreatic Neuroendocrine Tumor Bronchial Neuroendocrine Tumor

Summary

This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study tests a type of targeted radiation therapy called alpha-particle therapy in adults with neuroendocrine tumors (NETs) — slow-growing tumors that can form in the gut, lungs, or pancreas — that have progressed and have not previously received a specific type of radiation called PRRT. **You may be eligible if...** - You are 18 years or older - You have locally advanced, unresectable, or metastatic neuroendocrine tumors - Your tumors show a specific protein receptor (SSTR2) that allows them to be targeted by this therapy - You have not previously received PRRT (peptide receptor radionuclide therapy) - Your tumor has shown growth on imaging in the past 12 months **You may NOT be eligible if...** - You have previously had PRRT - Your tumor does not have the SSTR2 receptor - Your disease has not progressed in the last year Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[203Pb]VMT-α-NET

\[203Pb\]VMT-α-NET is administered by intravenous bolus injection for single-photon emission computed tomography imaging.

DRUG[212Pb]VMT-α-NET

\[212Pb\]VMT-α-NET is administered by intravenous infusion for treatment of SSTR2 expressing tumors.

Locations(19)

Mayo Clinic

Jacksonville, Florida, United States

Biogenix Molecular

Miami, Florida, United States

The University of Chicago

Chicago, Illinois, United States

University of Iowa

Iowa City, Iowa, United States

University of Kentucky

Lexington, Kentucky, United States

Johns Hopkins

Baltimore, Maryland, United States

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

BAMF Health

Grand Rapids, Michigan, United States

Michigan Health Professionals

Troy, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

Washington University

St Louis, Missouri, United States

Nebraska Cancer Specialists

Omaha, Nebraska, United States

University of North Carolina

Chapel Hill, North Carolina, United States

UH Cleveland Medical Center

Cleveland, Ohio, United States

Ohio State University

Columbus, Ohio, United States

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States

Virginia Cancer Specialists

Fairfax, Virginia, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States

Froedtert Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05636618

Related Trials

Diagnosis of Pheochromocytoma

NCT000048471 location

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

NCT032060601 location

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

NCT052782084 locations

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

NCT001072891 location

Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures

NCT074137961 location